DOI QR코드

DOI QR Code

Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma: is it different between Over and Under 50 Years of Age?

  • Monabati, Ahmad (Department of Pathology and Hematology Research Center, Shiraz University of Medical Sciences) ;
  • Vahedi, Amir (Department of Pathology, Liver and Gastrointestinal Disease Research Center, Tabriz University of Medical Sciences) ;
  • Safaei, Akbar (Department of Pathology, Shiraz University of Medical Sciences) ;
  • Noori, Sadat (Department of Pathology, Shiraz University of Medical Sciences) ;
  • Mokhtari, Maral (Department of Pathology, Shiraz University of Medical Sciences) ;
  • Vahedi, Leila (Liver and Gastrointestinal Disease Research Center, Tabriz University of Medical Sciences) ;
  • Zamani, Mehdi (Department of Pathology, Shiraz University of Medical Sciences)
  • Published : 2016.06.01

Abstract

Background: Epstein-Barr virus (EBV) positive diffuse large B-cell lymphoma (DLBCL) of the elderly is an entity introduced in the latest WHO classification of lymphoid tumors and defined in patients older than 50 years without prior lymphoma or immunodeficiency. However, recently it has also been seen in patients under 50. There is thus debate as to whether these are separate entities. Materials and Methods: In this retrospective study, we analyzed de novo DLBCL admitted to our institute over a period of two years. Clinical data included age, sex, nodal and extranodal presentation. The results of an immunohistochemistry (IHC) panel were also reviewed. IHC findings were mainly used to sub-classify DLBCL as germinal center vs. non germinal center types. IHC for identification of LMP-1 (latent membrane protein) and in situ hybridization for detection of EBV-encoded RNA (EBER) was performed. EBV prevalence, clinical data and IHC findings were compared between patients under and over 50 years of age. Results: Out of 95 DLBCL, 11.6% were EBV positive (7.5% and 14.5% in the young and old groups). We did not find any significant differences in IHC subclasses and clinical data between EBV positive DLBCL (EBV+DLBCL) of young and old groups. Conclusions: EBV+DLBCL are not exclusive to patients older than 50 years. With regard to clinical data as well as IHC subclasses, no differences were evident between EBV+DLBCL of young and old groups. Our suggestion is to eliminate any cut off age for EBV+DLBCL.

Keywords

Epstein barr virus;DLBCL;young age;old age;IHC subclasses

References

  1. Adam P, Bonzheim I, Fend F, et al (2011). Epstein-Barr viruspositive diffuse large B-cell lymphomas of the elderly. Adv Anat Pathol, 18, 349-55. https://doi.org/10.1097/PAP.0b013e318229bf08
  2. Akhtar S, Haque S. I. u, Wafa S. M, et al (2009). Malignant lymphoma in Al-Qassim, Saudi Arabia, reclassified according to the WHO classification. Saudi Med J, 30, 677-81.
  3. Anagnostopoulos I, Hummel M, Finn T, et al (1992). Heterogeneous Epstein-Barr virus infection patterns in peripheral T-cell lymphoma of angioimmunoblastic lymphadenopathy type. Blood, 80, 1804-12.
  4. Wang Ao. Q. Y, Tian S. Xu. Y, Huang W, et al (2014). A case of EBV positive diffuse large B-cell lymphoma of the adolescent. Int J Clin Exp Med, 7, 307-11
  5. Silva Aw D. A. B, Palmer D. B (2007). Immunosenescence: emerging challenges for an ageing population. Immunol, 120, 435-46. https://doi.org/10.1111/j.1365-2567.2007.02555.x
  6. Barrionuevo C, Anderson V. M, Zevallos-Giampietri E, et al (2002). Hydroa-like cutaneous T-cell lymphoma: a clinicopathologic and molecular genetic study of 16 pediatric cases from Peru. Appl Immunohistochem Mol Morphol, 10, 7-14.
  7. Beltran B. E, Castillo J. J, Morales D, et al (2011). EBV-positive diffuse large B-cell lymphoma of the elderly: A case series from Peru. Am J Hematol, 86, 663-67. https://doi.org/10.1002/ajh.22078
  8. Beltran B. E, Morales D, Quiñones P, et al (2011). EBV-positive diffuse large b-cell lymphoma in young immunocompetent individuals. Clin Lymphoma Myeloma Leuk, 11, 512-6. https://doi.org/10.1016/j.clml.2011.07.003
  9. Binesh F, Akhavan A, Behniafard N, et al (2013). Clinicopathologic and survival characteristics of childhood and adolescent non Hodgkin’s lymphoma in Yazd, Iran. Asian Pac J Cancer Prev, 15, 1585-8.
  10. Castillo J, Pantanowitz L, Dezube B. J (2008). HIV-associated plasmablastic lymphoma: Lessons learned from 112 published cases. Am J Hematol, 83, 804-9. https://doi.org/10.1002/ajh.21250
  11. Cohen J, Kimura H, Nakamura S, et al (2009). Epstein–Barr virus-associated lymphoproliferative disease in nonimmunocompromised hosts: a status report and summary of an international meeting, 8–9 September 2008. Ann Oncol, 20, 1472-82. https://doi.org/10.1093/annonc/mdp064
  12. Cohen M, Narbaitz M, Metrebian F, et al (2014). Epstein-Barr virus-positive diffuse large B-cell lymphoma association is not only restricted to elderly patients. Int J Cancer, 135, 2816-24. https://doi.org/10.1002/ijc.28942
  13. Dojcinov S. D, Venkataraman G, Pittaluga S, et al (2011). Agerelated EBV-associated lymphoproliferative disorders in the Western population: a spectrum of reactive lymphoid hyperplasia and lymphoma. Blood, 117, 4726-35. https://doi.org/10.1182/blood-2010-12-323238
  14. Dunleavy K, Roschewski M, Wilson W. H (2012). Lymphomatoid granulomatosis and other Epstein-Barr virus associated lymphoproliferative processes. Curr Hematol Malig Rep, 7, 208-15. https://doi.org/10.1007/s11899-012-0132-3
  15. Gibson S. E, Hsi E. D (2009). Epstein-Barr virus–positive B-cell lymphoma of the elderly at a United States tertiary medical center: an uncommon aggressive lymphoma with a nongerminal center B-cell phenotype. Hum Pathol, 40, 653-61. https://doi.org/10.1016/j.humpath.2008.10.007
  16. Hanif M, Zaidi P, Kamal S, et al (2009). Institution-based cancer incidence in a local population in Pakistan: nine year data analysis. Asian Pac J Cancer Prev, 10, 227-30.
  17. Hans C. P, Weisenburger D. D, Greiner T. C, et al (2004). Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood, 103, 275-82. https://doi.org/10.1182/blood-2003-05-1545
  18. Hecht J. L, Aster G.C (2000). Molecular biology of Burkitt’s lymphoma. J Clin Oncol, 18, 3707-21. https://doi.org/10.1200/JCO.2000.18.21.3707
  19. Hoeller S, Tzankov A, Pileri S.A, et al (2010). Epstein-Barr virus–positive diffuse large B-cell lymphoma in elderly patients is rare in Western populations. Hum Pathol, 41, 352-7. https://doi.org/10.1016/j.humpath.2009.07.024
  20. Hofscheier A, Ponciano A, Bonzheim I, et al (2011). Geographic variation in the prevalence of Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly: a comparative analysis of a Mexican and a German population. Mod Pathol, 24, 1046-54. https://doi.org/10.1038/modpathol.2011.62
  21. Hong J, Yoon D, Suh C, et al (2015). EBV-positive diffuse large B-cell lymphoma in young adults: is this a distinct disease entity? Ann Oncol, 26, 548-55. https://doi.org/10.1093/annonc/mdu556
  22. Hu S, Xu-Monette Z. Y, Tzankov A, et al (2013). MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. Blood, 121, 4021-31. https://doi.org/10.1182/blood-2012-10-460063
  23. Ishtiaq S, Hassan U, Mushtaq S, et al (2013). Determination of Frequency of Epstein-Barr Virus in Non-Hodgkin Lymphomas Using EBV Latent Membrane Protein 1 (EBVLMP1) Immunohistochemical Staining. Asian Pac J Cancer Prev, 14, 3963-7. https://doi.org/10.7314/APJCP.2013.14.6.3963
  24. Kanavaros P, Briere J, Emile J,et al (1996). Epstein-Barr virus in T and natural killer (NK) cell non-Hodgkin's lymphomas. Leukemia, 10, 84-87.
  25. Kilciksiz S, Pehlivan M, Yilmaz E, et al (2010). The clinical and pathological features of patients with hematological neoplasms: a study of hospital-based Cancer Registry from western Turkey. J BU ON, 16, 505-10.
  26. Kuze T, Nakamura N, Hashimoto Y, et al (2000). The characteristics of epstein-barr virus (EBV)-positive diffuse large B-cell lymphoma: comparison between EBV+ and EBV-cases in Japanese population. Jpn J Cancer Res, 91, 1233-40. https://doi.org/10.1111/j.1349-7006.2000.tb00909.x
  27. Lu TX, Liang JH, Miao Y, et al (2015). Epstein-Barr virus positive diffuse large B-cell lymphoma predict poor outcome, regardless of the age. Sci Rep, 5, 12168. https://doi.org/10.1038/srep12168
  28. Morales D, Beltran B, De Mendoza F. H, et al (2010). Epstein- Barr virus as a prognostic factor in de novo nodal diffuse large B-cell lymphoma. Leuk Lymphoma, 51, 66-72. https://doi.org/10.3109/10428190903308015
  29. Morton L. M, Wang S. S, Devesa S. S, et al (2006). Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood, 107, 265-76. https://doi.org/10.1182/blood-2005-06-2508
  30. Nakamura S, Jaffe E, Swerdlow S (2008). EBV positive diffuse large B-cell lymphoma of the elderly. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC, 243-44.
  31. Ok C. Y, Ye Q, Li L, et al (2015). Age cutoff for Epstein-Barr virus-positive diffuse large B-cell lymphoma-is it necessary? Oncotarget, 6, 13933-46. https://doi.org/10.18632/oncotarget.4324
  32. Otrock Z. K, Saab J, Aftimos G, et al (2013). A collaborative nationwide lymphoma study in Lebanon: incidence of various subtypes and analysis of associations with viruses. Pathol Oncol Res, 19, 715-22. https://doi.org/10.1007/s12253-013-9634-0
  33. Oyama T, Yamamoto K, Asano N, et al (2007). Age-related EBV-associated B-cell lymphoproliferative disorders constitute a distinct clinicopathologic group: a study of 96 patients. Clin Cancer Res, 13, 5124-32. https://doi.org/10.1158/1078-0432.CCR-06-2823
  34. Park S, Lee J, Ko Y. H, et al (2007). The impact of Epstein- Barr virus status on clinical outcome in diffuse large B-cell lymphoma. Blood, 110, 972-8. https://doi.org/10.1182/blood-2007-01-067769
  35. Quintanilla-Martinez L, de Jong D, de Mascarel A, et al (2009). Gray zones around diffuse large B cell lymphoma. Conclusions based on the workshop of the XIV meeting of the European Association for Hematopathology and the Society of Hematopathology in Bordeaux, France. J Hematopathol, 2, 211-36. https://doi.org/10.1007/s12308-009-0053-9
  36. Sabattini E, Bacci F, Sagramoso C, et al (2010). WHO classification of tumours of haematopoietic and lymphoid tissues in 2008: an overview. Pathologica, 102, 83-7.
  37. Shimoyama Y, Asano N, Kojima M, et al (2009). Agerelated EBV-associated B-cell lymphoproliferative disorders: Diagnostic approach to a newly recognized clinicopathological entity. Pathol Int, 59, 835-43. https://doi.org/10.1111/j.1440-1827.2009.02466.x
  38. Shimoyama Y, Yamamoto K, Asano N, et al (2008). Age-related Epstein–Barr virus-associated B-cell lymphoproliferative disorders: Special references to lymphomas surrounding this newly recognized clinicopathologic disease. Cancer Sci, 99, 1085-91. https://doi.org/10.1111/j.1349-7006.2008.00813.x
  39. Uccini S, Al-Jadiry M. F, Scarpino S, et al (2015). Epstein-Barr virus–positive diffuse large B-cell lymphoma in children: a disease reminiscent of Epstein-Barr virus–positive diffuse large B-cell lymphoma of the elderly. Hum Pathol, 46, 716-24. https://doi.org/10.1016/j.humpath.2015.01.011

Cited by

  1. New developments in the pathology of malignant lymphoma: a review of the literature published from June–August 2016 vol.9, pp.3, 2016, https://doi.org/10.1007/s12308-016-0284-5
  2. Pediatric Pulmonary Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma: A Case Report and Review of the Literature vol.2017, pp.2090-679X, 2017, https://doi.org/10.1155/2017/8946807